TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 13, Issue 2, 2011, Pages

  Dharmapatni, Anak A S S K ^a   Smith, Malcolm D ^b   Crotti, Tania N ^a   Holding, Christopher A ^a   Vincent, Cristina ^d   Weedon, Helen M ^b   Zannettino, Andrew C W ^c,e   Zheng, Timothy S ^d   Findlay, David M ^a,e   Atkins, Gerald J ^a,e   Haynes, David R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d BIOGEN   (United States)

^e HANSON INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; CD38 ANTIGEN; CD68 ANTIGEN; CELL SURFACE MARKER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN FN14; TNF LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; TRYPTASE; UNCLASSIFIED DRUG; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTHRITIS; ARTICLE; BONE EROSION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IN VITRO STUDY; MALE; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; SYNOVIAL FLUID; SYNOVIUM; B LYMPHOCYTE; BIOSYNTHESIS; CELL SEPARATION; CHEMISTRY; INFLAMMATION; KNEE OSTEOARTHRITIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PLASMA CELL;

AGED; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; OSTEOBLASTS; PLASMA CELLS; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL FLUID; TUMOR NECROSIS FACTORS;

EID: 79953093604     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3294     Document Type: Article

References (40)

1. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007, 40:1-16. 10.1016/j.cyto.2007.09.007, 17981048.
2. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425. 10.1038/nrd2488, 3018765, 18404150.
3. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 2003, 371:395-403. 10.1042/BJ20021730, 1223299, 12529173.
4. Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004, 9:2273-2284. 10.2741/1395, 15353286.
5. Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, Hwang K, Young Lee S. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun 2003, 305:789-796. 10.1016/S0006-291X(03)00852-0, 12767899.
6. Campbell S, Burkly LC, Gao HX, Berman JW, Su L, Browning B, Zheng T, Schiffer L, Michaelson JS, Putterman C. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006, 176:1889-1898.
7. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002, 299:488-493. 10.1016/S0006-291X(02)02670-0, 12445828.
8. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol 2006, 146:540-549. 10.1111/j.1365-2249.2006.03233.x, 1810398, 17100776.
9. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, Dayer JM. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002, 4:126-133. 10.1186/ar388, 83846, 11879548.
10. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H. TWEAK is a novel arthritogenic mediator. J Immunol 2006, 177:2610-2620.
11. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, Okumura K. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 2006, 177:6433-6439.
12. Kamijo S, Nakajima A, Kamata K, Kurosawa H, Yagita H, Okumura K. Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. Rheumatology (Oxford) 2008, 47:442-450. 10.1093/rheumatology/ken006, 18310134.
13. Park MC, Jung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008, 37:173-178. 10.1080/03009740801898608, 18465450.
14. van Kuijk AW, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to TNF blockade. Ann Rheum Dis 2009, 69:301-304.
15. Xia LP, Xiao WG, Li JS, Ding S, Lu J. Effects of TWEAK on the synthesis of MMP-3 in fibroblast-like synoviocytes of rheumatoid arthritis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009, 25:46-48.
16. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009, 24:1434-1449. 10.1359/jbmr.090305, 19292615.
17. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003, 278:32317-32323. 10.1074/jbc.M302518200, 12794080.
18. Williams SA, Martin SK, Vincent C, Gronthos S, Zheng T, Atkins GJ, Zannettino AC. Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. Br J Haematol 2010, 150:373-376. 10.1111/j.1365-2141.2010.08201.x, 20408838.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
20. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29:1039-1049. 10.1002/art.1780290816, 3741515.
21. Smith MD, Barg E, Weedon H, Papengelis V, Smeets T, Tak PP, Kraan M, Coleman M, Ahern MJ. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis 2003, 62:303-307. 10.1136/ard.62.4.303, 1754505, 12634226.
22. Kraan MC, Haringman JJ, Post WJ, Versendaal J, Breedveld FC, Tak PP. Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatology (Oxford) 1999, 38:1074-1080. 10.1093/rheumatology/38.11.1074, 10556258.
23. Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ, Weedon H, Chen P, Screaton G, Xu XN, Haynes DR. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 2009, 11:R13. 2688245, 19171073.
24. Gomori E, Pal J, Abraham H, Vajda Z, Sulyok E, Seress L, Doczi T. Fetal development of membrane water channel proteins aquaporin-1 and aquaporin-4 in the human brain. Int J Dev Neurosci 2006, 24:295-305. 10.1016/j.ijdevneu.2006.05.003, 16814974.
25. Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, Evdokiou A, Zannettino AC. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006, 21:1339-1349. 10.1359/jbmr.060604, 16939392.
26. Vincent C, Kogawa M, Findlay DM, Atkins GJ. The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. J Bone Miner Metab 2009, 27:114-119. 10.1007/s00774-008-0018-6, 19057837.
27. Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78:55-62.
28. Atkins GJ, Welldon KJ, Halbout P, Findlay DM. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2008, 20:653-664. 10.1007/s00198-008-0728-6, 18763010.
29. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Current Opinion in Immunology 2005, 17:290. 10.1016/j.coi.2005.03.005, 15886119.
30. Dorner T, Goldenberg DM. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag 2007, 3:953-959. 2376077, 18473018.
31. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001, 40:623-630. 10.1093/rheumatology/40.6.623, 11426018.
32. Kataria N, Bartold PM, Dharmapatni AASK. Expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor, fibroblast growth factor-inducible 14 protein (Fn14), in healthy tissues and tissues affected by periodontitis. J Periodontal Res 2010, 45:564-573.
33. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999, 274:8455-8459. 10.1074/jbc.274.13.8455, 10085077.
34. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003, 23:594-600. 10.1161/01.ATV.0000062883.93715.37, 12615668.
35. Nicholson GC, Malakelis M, Collier FM, Cameron PU, Holloway W, Gough TJ, Gregorio-King C, Kirkland MA, Myers DE. Induction of osteoclast from CD14-positive human peripheral blood mononuclear cells by activator of nuclear factor kappaB ligand (RANKL). Clin Sci (Lond) 2000, 99:133-140. 10.1042/CS19990355, 10918046.
36. Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol 2005, 203:573-582. 10.1002/jcp.20255, 15573398.
37. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003, 18:1088-1098. 10.1359/jbmr.2003.18.6.1088, 12817763.
38. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res 2010, 25:1897-1904. 10.1002/jbmr.161, 20564241.
39. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby RT, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM. Sclerostin is a locally acting regulator of late-osteoblast/pre-osteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res 2011,
40. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009, 24:1572-1585. 10.1359/jbmr.090320, 19338457.